Product Specification
| Alternative Name: | Serine/threonine protein kinase VRK1, Vaccinia-related kinase 1 |
| |
| Clone: | 1F6 |
| |
| Host: | Mouse |
| |
| Isotype: | IgG1 |
| |
| Immunogen: | Recombinant human VRK1 (vaccinia-related kinase 1). |
| |
| UniProt ID: | Q99986 |
| |
| Source: | Purified from concentrated hybridoma tissue culture supernatant. |
| |
| Species reactivity: | Human
|
| |
| Crossreactivity: | Does not cross-react with mouse or rat VRK1. |
| |
| Applications: | IHC (PS), IP, WB
|
| |
| Recommended Dilutions/Conditions: | Immunohistochemistry (1:500)
Western Blot (1:1,000-1:10,000)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application. |
| |
| Purity Detail: | Protein G-affinity purified |
| |
| Formulation: | Liquid. In PBS containing 0.02% sodium azide. |
| |
| Use/Stability: | Stable for at least 1 year after receipt when stored at -20°C. |
| |
| Handling: | Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C. |
| |
| Shipping: | Shipped on Blue Ice |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Scientific Background: | Vaccinia-related kinase 1 (VRK1) contributes to p53 stabilization by partly interfering with its MDM2-mediated degradation. |
| |
Figure: Western Blot of endogenous Vaccinia-related Kinase 1 (VRK1) (human) by the MAb to VRK1(1F6) (Prod. No.
ALX-803-321).
Method: Total cell extracts (10µg) of human embryo kidney 293 (HEK293) (lane 1) and HeLa (lane 2) cell lines were run on a SDS-gel, and revealed with MAb to VRK1(1F6) (1:1’000) for 1 hour at room temperature followed by incubation with HRP-coupled goat-anti mouse antibody (1:4’000). The arrow indicates endogenous VRK1. "
Please mouse over
Product Literature References
Plk3 interacts with and specifically phosphorylates VRK1 in Ser342, a downstream target in a pathway that induces Golgi fragmentation.: I. López- Sánchez, et al.; Mol. Cell Biol.
29, 1189 (2009),
Abstract;
A central role for CK1 in catalyzing phosphorylation of the p53 transactivation domain at serine 20 after HHV-6B viral infection: N.J. MacLaine; J. Biol. Chem.
283, 28563 (2008),
Abstract;
Human VRK1 Is an Early Response Gene and Its Loss Causes a Block in Cell Cycle Progression: A. Valbuena, et al.; PLOS ONE
3, e1642 (2008),
Abstract;
Proteomic identification of nuclear Ran GTPase as an inhibitor of human VRK1 and VRK2 (Vaccinia-Related Kinase) activities: M. Sanz-García; Mol. Cell. Proteomics
7, 2199 (2008),
Abstract;
Identification of a dominant epitope in human vaccinia-related kinase 1 (VRK1) and detection of different intracellular subpopulations: A. Valbuena, et al.; Arch. Biochem. Biophys.
465, 219 (2007),
Abstract;
VRK1 signaling pathway in the context of the proliferation phenotype in head and neck squamous cell carcinoma: C.R. Santos, et al.; Mol. Cancer Res.
4, 177 (2006),
Abstract;
p53 Stabilization and accumulation induced by human vaccinia-related kinase 1: F.M. Vega, et al.; Mol. Cell. Biol.
24, 10366 (2004),
Abstract;
